Many of our drug candidates are available for out-licensing in regions outside the U.S., such as Europe and Asia. The following is a list of our proprietary drugs available for co-development:
In addition, as part of Spectrum’s strategy to focus on oncology and urology, Spectrum has a portfolio of neurology drug candidates that are available for out-licensing. A list and description of these opportunities can be found below.
For more information regarding these compounds and all our various out-licensing options, please contact nikhil.gadre@sppirx.com.
